The DOI matches its Crossref record.
Long‐term surveillance of mortality and cancer incidence in women receiving hormone replacemen therapy
Abstract
Summary: This paper reports the preliminary results of a cohort study of 4544 British women receiving hormone replacement therapy (HRT). These women were recruited at 21 specialist menopause clinics around Britain. Up to the end of June 1983, the mean duration of HRT use per woman was 67 months of which, on average, 43% was‘opposed’use. In general, however, both the amount of progestogen given and the number of days per cycle for which it was given was less than would have been the case if the women had been receiving modern opposed therapy. The major focus of the study was to monitor mortality and cancer incidence in the cohort. The mortality results were broadly reassuring: overall mortality was significantly lower than expected on the basis of national rates (relative risk 0·58) and mortality ratios were below unity for all specific causes of death examined apart from cancer of the ovary (relative risk 1·43, 95% confidence limits 0·62–2·82) and suicide or suspected suicide (relative risk 2·53, 95% confidence limits 1·26–4·54). The most likely explanation for the latter finding is selection bias—thus at least 7 of the 11 women who died from suicide or suspected suicide had a psychiatric history before receiving HRT. The cancer incidence results were less reassuring, although they should be interpreted with some caution because cancer registry rates were used for comparative purposes. With this proviso, endometrial cancer risk was significantly elevated (relative risk 2·84,95% confidence iimits 1·46–4·96); many of the women concerned had taken therapy which was predominantly or entirely opposed although only one woman had received an opposed regimen which would now be considered adequately protective to the endometrium. Breast cancer incidence was also significantly increased (relative risk 1·59, 95% confidence limits 1·18–2·10); detailed analysis suggested that the use of unopposed ethinyloestradiol in particular might have undesirable effects on the breast.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487
Estrogen and coronary heart disease in women
Barrett-Connor, E. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460140089033 · Cited by 1,241
Decreased Mortality in Users of Estrogen Replacement Therapy
Henderson, B. E. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400010095012 · Cited by 632
The epidemiology of breast cancer
Kelsey, J. L., & Gammon, M. D. (1991) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.41.3.146 · Cited by 143
Metadata
- Authors
- HUNT, K., VESSEY, M., MCPHERSON, K., & COLEMAN, M.
- Venue
- BJOG: An International Journal of Obstetrics & Gynaecology
- Publisher
- Wiley
- Published
- 1987-07
- Volume
- 94
- Issue
- 7
- Pages
- 620-635
- ISSN
- 0306-5456 (ISSN-L)
- 1470-0328
- 1471-0528
- OpenAlex
- W2152483384
- Cited by
- 288
- References
- 0
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term surveillance of mortality and cancer incidence in women receiving hormone replacemen therapy. https://app.cochat.ai/papers/10.1111/j.1471-0528.1987.tb03166.x
- The paper
- HUNT, K., VESSEY, M., MCPHERSON, K., & COLEMAN, M. (1987). Long‐term surveillance of mortality and cancer incidence in women receiving hormone replacemen therapy. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/j.1471-0528.1987.tb03166.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.